Trollor, JN, Chen, X, Chitty, K, Sachdev, PS. Comparison of neuroleptic malignant syndrome induced by first- and second-generation antipsychotics. Br J Psychiatry
2012; 201: 52–6.
Langan, J, Martin, D, Shajahan, P, Smith, DJ. Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report. BMC Psychiatry
2012; 12: 214.
Strawn, JR, Keck, PE, Caroff, SN. Neuroleptic malignant syndrome. Am J Psychiatry
2007; 164: 870–6.
Gurrera, RJ, Caroff, SN, Cohen, A, Carroll, BT, DeRoos, F, Francis, A, et al. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry
2011; 72: 1222–8.
Adityanjee, , Sajatovic, M, Munshi, KR. Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol
2005; 28: 197–204.
Modi, S, Dharaiya, D, Schultz, L, Varelas, P. Neuroleptic malignant syndrome: complications, outcomes, and mortality. Neurocritical Care
2016; 24: 97–103.
Nakamura, M, Yasunaga, H, Miyata, H, Shimada, T, Horiguchi, H, Matsuda, S. Mortality of neuroleptic malignant syndrome induced by typical and atypical antipsychotic drugs: a propensity-matched analysis from the Japanese Diagnosis Procedure Combination database. J Clin Psychiatry
2012; 73: 427–30.
Tarsy, D, Baldessarini, RJ, Tarazi, FL. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs
2002; 16: 23–45.
Belvederi Murri, M, Guaglianone, A, Bugliani, M, Calcagno, P, Respino, M, Serafini, G, et al. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs RD
2015; 15: 45–62.
Trollor, JN, Chen, X, Sachdev, PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs
2009; 23: 477–92.
Pope, HG, Cole, JO, Choras, PT, Fulwiler, CE. Apparent neuroleptic malignant syndrome with clozapine and lithium. J Nerv Ment Dis
1986; 174: 493–5.
Patel, NC, Crismon, ML, Hoagwood, K, Johnsrud, MT, Rascati, KL, Wilson, JP, et al. Trends in the use of typical and atypical antipsychotics in children and adolescents. J Am Acad Child Adolesc Psychiatry
2005; 44: 548–56.
Verdoux, H, Tournier, M, Bégaud, B. Antipsychotic prescribing trends: a review of pharmacoepidemiological studies. Acta Psychiatr Scand
Buckley, PF. Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry
2001; 50: 912–24.
Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ
2000; 321: 1371–6.
Owens, DC. How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia. Adv Psychiatr Treat
2008; 14: 17–28.
Ananth, J, Parameswaran, S, Gunatilake, S, Burgoyne, K, Sidhom, T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry
2004; 65: 464–70.
Jann, MW, Grimsley, SR, Gray, EC, Chang, WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet
1993; 24: 161–76.
Amore, M, Zazzeri, N, Berardi, D. Atypical neuroleptic malignant syndrome associated with clozapine treatment. Neuropsychobiology
1997; 35: 197–9.
Karagianis, JL, Phillips, LC, Hogan, KP, LeDrew, KK. Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. Ann Pharmacother
1999; 33: 623–30.
Licup, N, Baumrucker, SJ. Olanzapine for nausea and vomiting. Am J Hosp Palliat Care
2010; 27: 432–4.
Musshoff, F, Doberentz, E, Madea, B. Lethal neuroleptic malignant syndrome due to amisulpride. Forensic Sci Med Pathol
2013; 9: 218–20.
Tsai, JH, Yang, P, Yen, JY, Chen, CC, Yang, MJ. Zotepine-induced catatonia as a precursor in the progression to neuroleptic malignant syndrome. Pharmacotherapy
2005; 25: 1156–9.
Horacek, J, Bubenikova-Valesova, V, Kopecek, M, Palenicek, T, Dockery, C, Mohr, P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs
2006; 20: 389–409.
Detweiler, MB, Sullivan, K, Sharma, TR, Kim, KY, Detweiler, JG. Case reports of neuroleptic malignant syndrome in context of quetiapine use. Psychiatr Q
2013; 84: 523–41.
Chen, Y-T, Su, K-P, Chang, JP-C. Early detection and management of atypical neuroleptic malignant syndrome secondary to aripiprazole. Schizophr Res
2011; 132: 97–8.
Tseng, PT, Chang, YC, Chang, CH, Wang, HY, Cheng, YS, Wu, CK, et al. Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review. Int J Psychiatry Med
2015; 49: 35–43.
Leibold, J, Patel, V, Hasan, RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Therapeut
2004; 26: 1105–8.
Ozen, ME, Yumru, M, Savas, HA, Cansel, N, Herken, H. Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment. World J Biol Psychiatry
2007; 8: 42–4.
Mantas, C, Kalabokis, G, Goulia, P, Tourlakopoulos, A, Hyphantis, T, Mavreas, V. Possible neuroleptic malignant syndrome during paliperidone administration: a case report. J Clin Psychopharmacol
2010; 30: 89–91.
Teng, PR, Lane, HY. Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone. J Neuropsychiatry Clin Neurosci
2011; 23: E16.
Hsu, W-C, Lin, S-T, Chen, C-C, Tsang, H-Y, Huang, M-F. A self-limiting case of atypical neuroleptic malignant syndrome associated with zotepine. J Clin Psychopharmacology
2011; 31: 667–9.
Guanci, N, Aggarwal, R, Schleifer, S. Atypical neuroleptic malignant syndrome associated with iloperidone administration. Psychosomatics
2012; 53: 603–5.
Ohoyama, K, Tanii, H, Motomura, E, Konishi, Y, Nakagawa, M, Matsumoto, T, et al. Neuroleptic malignant syndrome induced by blonanserin. J Neuropsychiatry Clin Neurosci
2011; 23: E13.
Patel, MK, Brunetti, L. Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient. Am J Health Syst Pharm
2010; 67: 1254–9.
Borovicka, MC, Bond, LC, Gaughan, KM. Ziprasidone- and lithium-induced neuroleptic malignant syndrome. Ann Pharmacother
2006; 40: 139–42.
Su, YP, Chang, CK, Hayes, RD, Harrison, S, Lee, W, Broadbent, M, et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand
2014; 130: 52–60.
Picard, LS, Lindsay, S, Strawn, JR, Kaneria, RM, Patel, NC, Keck, PE Jr. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy
2008; 28: 530–5.
Caroff, SN, Mann, SC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatr Ann
2000; 30: 314–21.
Levenson, JL. Neuroleptic malignant syndrome. Am J Psychiatry
1985; 142: 1137–45.
Addonizio, G, Susman, VL, Roth, SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry
1986; 143: 1587–90.
Odagaki, Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?
Cure Drug Saf
2009; 4: 84–93.
Susman, VL. Clinical management of neuroleptic malignant syndrome. Psychiatr Q
2001; 72: 325–36.
Frucht, SJ. Treatment of movement disorder emergencies. Neurotherapeutics
2014; 11: 208–12.
Anbalagan, E, Ithman, M, Lauriello, J. Rechallenging clozapine after neuroleptic malignant syndrome. Psychiatr Q
2014; 85: 345–8.
Manu, P, Sarpal, D, Muir, O, Kane, JM, Correll, CU. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res
2012; 134: 180–6.
Mendhekar, DN, Jiloha, RC, Mehndiratta, MM, War, L. Challenge with atypical antipsychotic drugs in risperidone induced neuroleptic malignant syndrome: a case report. In J Psychiatry
2002; 44: 387–90.
Ross, C. Successful clozapine rechallenge following clozapine-induced neuroleptic malignant syndrome. Ment Health Clin
2015; 5: 88–90.